2-((2-ethyl-6-methylpyridin-3-yl)oxy)acetic acid | 132401-72-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-((2-ethyl-6-methylpyridin-3-yl)oxy)acetic acid
• 英文别名: 2-(2-ethyl-6-methylpyridin-3-yl)oxyacetic acid
• CAS: 132401-72-0
• 化学式: C₁₀H₁₃NO₃
• mdl: MFCD00462402
• 分子量: 195.218
• InChiKey: MTXHAAUHPXVFAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-chloro-2-fluorophenyl)-1,2,3,4,6,7,8,9-octahydroimidazo[1,2-a:5,4-c']dipyridine 、 2-((2-ethyl-6-methylpyridin-3-yl)oxy)acetic acid 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以23 %的产率得到1-(1-(4-chloro-2-fluorophenyl)-3,4,6,7,8,9-hexahydroimidazo-[1,2-a:5,4-c′]dipyridin-2(1H)-yl)-2-((2-ethyl-6-methylpyridin-3-yl)-oxy) ethan-1-one
  参考文献：
  名称：

  Structure-Based Design of Xanthine-Imidazopyridines and -Imidazothiazoles as Highly Potent and In Vivo Efficacious Tryptophan Hydroxylase Inhibitors

  摘要：

  DOI：

  10.1021/acs.jmedchem.3c01454
• 作为产物：
  描述：

  2-乙基-6-甲基-3-羟基吡啶 在 sodium hydroxide 、 potassium carbonate 作用下， 以 乙醇 、 水 为溶剂， 反应 14.0h， 生成 2-((2-ethyl-6-methylpyridin-3-yl)oxy)acetic acid
  参考文献：
  名称：

  2-和6-取代（pyride-3-iloxy）乙酸衍生物的合成和药理活性

  摘要：

  I及其代谢物在机体内部介质和胃肠道中的发生与[2, 6]一致。从分析单次给药结果获得的计算数据表明，胃肠道中放射性物质的每日波动高于人体内部介质，分别等于 1.19-0.4 Q 和 0.46-0.25 Q。此处提供的数据表明 14C-制备物被迅速消除，并且在实验动物中没有 14C-I 及其代谢物的积累。

  DOI：

  10.1007/bf00767026

文献信息

• [EN] TRICYCLIC PIPERIDINE COMPOUNDS<br/>[FR] COMPOSÉS PIPÉRIDINIQUES TRICYCLIQUES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2016177690A1

  公开（公告）日：2016-11-10

  The present invention relates to compounds of the formula (I) wherein R1a, R1b, R2, R3, (R4)n and ring (A) are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

  本发明涉及式(I)的化合物，其中R1a、R1b、R2、R3、(R4)n和环(A)如描述中所述，其制备方法，其药学上可接受的盐，以及作为药物的用途，含有一个或多个式(I)化合物的药物组合物，制备这种式(I)化合物的方法，特别是作为TPH调节剂的用途。
• Synthesis and pharmacological activity of imidazo[4,5-c]pyridine derivatives
  作者：O. M. Glozman、É. K. Orlova、L. M. Meshcheryakova、T. A. Voronina、T. L. Garibova、N. V. Markina、L. D. Smirnov

  DOI：10.1007/bf00766375

  日期：1989.8

  Derivatives of imidazo[4,5-c]pyridlne (IP) show a variety of pharmacological activities [3, 9]. In particular, there are IP derivatives active as GABAergir agonists and selective anxiolytic antagonists [2, 8]. To investigate the neurotropic activity of IP derivatives, four compounds (la-d) were prepared with adamantyl, dipropylmethyl, 4-chlorophenoxymethyl, and pyridyl-3-oxymethyl moieties as the pharmacophore

  咪唑并 [4,5-c] 吡啶 (IP) 的衍生物显示出多种药理活性 [3, 9]。特别是，有作为 GABAergir 激动剂和选择性抗焦虑拮抗剂的 IP 衍生物 [2, 8]。为了研究 IP 衍生物的神经活性，制备了四种化合物 (la-d)，其中金刚烷基、二丙基甲基、4-氯苯氧基甲基和吡啶基-3-氧基甲基部分作为 IP 位置 2 的药效基团。
• Synthesis and pharmacological activity of 2- and 6-substituted (pyride-3-iloxy)acetic acid derivatives
  作者：T. A. Voronina、O. M. Glozman、E. K. Orlova、V. I. Kuz'min、L. D. Smirnov、T. L. Garibova、I. V. Khromova、V. Zauer、A. Rostok、Kh. Zigemund

  DOI：10.1007/bf00767026

  日期：1990.9

  I and its metabolites in the internal medium of the body and the GI tract occurred in agreement with [2, 6]. The computed data obtained from analyzing the results of a single administration demonstrate that the daily fluctuations of radioactive material in the GI tract are higher than in the body's internal medium and are equal to 1.19-0.4 Q and 0.46-0.25 Q respectively. The data here presented indicate

  I及其代谢物在机体内部介质和胃肠道中的发生与[2, 6]一致。从分析单次给药结果获得的计算数据表明，胃肠道中放射性物质的每日波动高于人体内部介质，分别等于 1.19-0.4 Q 和 0.46-0.25 Q。此处提供的数据表明 14C-制备物被迅速消除，并且在实验动物中没有 14C-I 及其代谢物的积累。
• TRICYCLIC PIPERIDINE COMPOUNDS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20160272655A1

  公开（公告）日：2016-09-22

  The present invention relates to compounds of the formula (I) wherein R, R 1a , R 1b , R 2 , R 3 , and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

  本发明涉及式（I）的化合物，其中R、R1a、R1b、R2、R3和X如描述中所述，其制备方法，其药学上可接受的盐以及它们作为药物的用途，含有一个或多个式（I）化合物的药物组合物，制备这种式（I）化合物的方法，特别是它们作为TPH调节剂的用途。
• Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US10189839B2

  公开（公告）日：2019-01-29

  The present invention relates to compounds of the formula (I) wherein R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

  本发明涉及式 (I) 的化合物 其中 R1a、R1b、R2、R3 和 X 如描述中所述，涉及它们的制备，涉及它们的药学上可接受的盐，涉及它们作为药物的用途，涉及含有一种或多种式（I）化合物的药物组合物，涉及这种式（I）化合物的制备方法，尤其涉及它们作为 TPH 调节剂的用途。